Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 543

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study

Narod, Steven A, Brunet, Jean-Sébastien, Ghadirian, Parviz, Robson, Mark, Heimdal, Ketil, Neuhausen, Susan L, Stoppa-Lyonnet, Dominique, Lerman, Caryn, Pasini, Barbara, de los Rios, Patricia, Weber, Barbara, Lynch, Henry·2000·The Lancet
DOI 10.1016/s0140-6736(00)03258-x
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(00)03258-x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 31

  1. Narod, 1995, An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families, Am J Hum Genet, 56, 254
  2. Ford, 1998, Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families, Am J Hum Genet, 62, 676, 10.1086/301749 · DOI · Paper page
  3. Struewing, 1997, The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Engl J Med, 336, 1401, 10.1056/NEJM199705153362001 · DOI · Paper page
  4. Thorlacius, 1998, Population-based study of risk of breast cancer in carriers of BRCA2 mutation, Lancet, 352, 1337, 10.1016/S0140-6736(98)03300-5 · DOI · Paper page
  5. Robson, 1998, BRCA-associated breast cancer in young women, J Clin Oncol, 16, 1642, 10.1200/JCO.1998.16.5.1642 · DOI · Paper page
  6. Hartmann, 1998, Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, N Engl J Med, 340, 77, 10.1056/NEJM199901143400201 · DOI · Paper page
  7. Fisher, 1998, Tamoxifen for prevention of breast cancer; report of the National Surgical Adjuvant Breast and Bowel Project PI study, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371 · DOI · Paper page
  8. 1998, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 · DOI · Paper page
  9. Hogervorst, 1995, Rapid detection of BRCA1 mutations by the protein truncation test, Nat Genet, 10, 208, 10.1038/ng0695-208 · DOI · Paper page
  10. Tonin, 1996, Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families, Nat Med, 11, 1179, 10.1038/nm1196-1179 · DOI · Paper page
  11. Tonin, 1998, Founder BRCA1 and BRCA2 mutations in French-Canadian breast and ovarian cancer families, Am J Hum Genet, 63, 1341, 10.1086/302099 · DOI · Paper page
  12. Karp, 1997, Influence of BRCA1 mutations on nuclear grade and estrogen receptor status in breast cancers in Ashkenazi Jewish women, Cancer, 80, 435, 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y · doi:10.1002/(sici)1097-0142(19970801)80:3<435::aid-cncr11>3.0.co;2-y
  13. Johannsson, 1997, Tumour biological features of BRCA1-induced breast and ovarian cancer, Eur J Cancer, 33, 362, 10.1016/S0959-8049(97)89007-7 · DOI · Paper page
  14. Loman, 1998, Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes, Cancer, 83, 310, 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W · DOI · Paper page
  15. Eisenger, 1999, Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes, Cancer, 85, 2291, 10.1002/(SICI)1097-0142(19990515)85:10<2291::AID-CNCR26>3.0.CO;2-9 · doi:10.1002/(sici)1097-0142(19990515)85:10<2291::aid-cncr26>3.0.co;2-9
  16. Narod, 1995, Risk modifiers in carriers of BRCA1 mutations, Int J Cancer, 64, 394, 10.1002/ijc.2910640608 · DOI · Paper page
  17. Easton, 1995, Breast and ovarian cancer incidence in BRCA1 mutation carriers, Am J Hum Genet, 56, 265
  18. Rebbeck, 1999, Reduction in breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers, J Natl Cancer Inst, 91, 1475, 10.1093/jnci/91.17.1475 · DOI · Paper page
  19. Jernström, 1999, Pregnancy and risk of early onset breast cancer in carriers of BRCA1 and BRCA2, Lancet, 354, 1846, 10.1016/S0140-6736(99)04336-6 · DOI · Paper page
  20. Brunet, 1998, The effect of smoking on breast cancer incidence in BRCA1 and BRCA2 carriers, J Natl Cancer Inst, 90, 761, 10.1093/jnci/90.10.761 · DOI
  21. Fan, 1999, BRCA1 inhibition of estrogen receptor signalling in transfected cells, Science, 284, 1354, 10.1126/science.284.5418.1354 · DOI · Paper page
  22. Veronesi, 1998, Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women, Lancet, 352, 93, 10.1016/S0140-6736(98)85011-3 · doi:10.1016/s0140-6736(98)85011-3 · Paper page
  23. Powles, 1998, Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial, Lancet, 352, 98, 10.1016/S0140-6736(98)05071-5 · DOI · Paper page
  24. 1999, Cancer risks in BRCA2 carriers, J Natl Cancer Inst, 91, 1310, 10.1093/jnci/91.15.1310 · DOI · Paper page
  25. Moslehi, 2000, BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer, Am J Hum Genet, 66, 1259, 10.1086/302853 · DOI · Paper page
  26. Cummings, 1999, The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial, JAMA, 281, 2189, 10.1001/jama.281.23.2189 · DOI · Paper page
  27. Chen, 1999, Epidemiology of contralateral breast cancer, Cancer Epidemiol Biomarkers Prev, 8, 855
  28. 1997, Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases, Lancet, 349, 1505, 10.1016/S0140-6736(96)10109-4 · DOI · Paper page
  29. Crook, 1997, p53 mutations in BRCA1-associated familial breast cancer, Lancet, 350, 638, 10.1016/S0140-6736(05)63327-2 · DOI · Paper page
  30. Meakin, 1996, Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast, Breast Cancer Res Treat, 37, 11, 10.1007/BF01806627 · doi:10.1007/bf01806627
  31. O'Reagan, 1999, Tamoxifen and contralateral breast cancer, J Am Coll Surg, 188, 678, 10.1016/S1072-7515(99)00057-5 · doi:10.1016/s1072-7515(99)00057-5

Cited by

See all 543

Metadata

Authors
Narod, S. A., Brunet, J.-S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., Weber, B., & Lynch, H.
Venue
The Lancet
Publisher
Elsevier BV
Published
2000-12
Volume
356
Issue
9245
Pages
1876-1881
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(00)03258-x
OpenAlex
W2009074196
Cited by
543
References
3
FWCI
23.75
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. https://app.cochat.ai/papers/10.1016/s0140-6736(00)03258-x
The paper
Narod, S. A., Brunet, J.-S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., de los Rios, P., Weber, B., & Lynch, H. (2000). Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. The Lancet. https://doi.org/10.1016/s0140-6736(00)03258-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.